Repository logo

Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype

Published version

Change log


Purcell, Siobhan P. 
Cosgrove, Nicola S. 
Cocchiglia, Sinéad  ORCID logo


Abstract: Steroid regulated cancer cells use nuclear receptors and associated regulatory proteins to orchestrate transcriptional networks to drive disease progression. In primary breast cancer, the coactivator AIB1 promotes estrogen receptor (ER) transcriptional activity to enhance cell proliferation. The function of the coactivator in ER+ metastasis however is not established. Here we describe AIB1 as a survival factor, regulator of pro-metastatic transcriptional pathways and a promising actionable target. Genomic alterations and functional expression of AIB1 associated with reduced disease-free survival in patients and enhanced metastatic capacity in novel CDX and PDX ex-vivo models of ER+ metastatic disease. Comparative analysis of the AIB1 interactome with complementary RNAseq characterized AIB1 as a transcriptional repressor. Specifically, we report that AIB1 interacts with MTA2 to form a repressive complex, inhibiting CDH1 (encoding E-cadherin) to promote EMT and drive progression. We further report that pharmacological and genetic inhibition of AIB1 demonstrates significant anti-proliferative activity in patient-derived models establishing AIB1 as a viable strategy to target endocrine resistant metastasis. This work defines a novel role for AIB1 in the regulation of EMT through transcriptional repression in advanced cancer cells with a considerable implication for prognosis and therapeutic interventions.


Funder: Breast Cancer Ireland GR 14-0883


Article, /631/67/1347, /631/67/322, /38/91, /38/39, /82/58, /13/51, /64/60, /96/106, /13/89, article

Journal Title


Conference Name

Journal ISSN


Volume Title



Nature Publishing Group UK
Irish Cancer Society (CCRC13GAL, STB19VAR)
Breast Cancer Now (BCN) (2018JulPR1094)
Breast Cancer Now (2019AugSF1310)